Teneliximab is a chimeric monoclonal antibody[1] binding to the immune stimulatory protein CD40.

[2] As of 2009[update], it has not entered clinical trials.

[2] Immune activation: Dostarlimab Other: Ibalizumab

This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.